Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology - United States
doi 10.1200/jco.2005.02.4786
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Diffuse Large B-Cell Lymphoma

2020English

Prognostic Significance of Serum Aspartic Transaminase in Diffuse Large B-Cell Lymphoma

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Diffuse Large B-Cell Lymphoma: Using Immune Biomarkers to Define Novel Therapies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Prognostic Nomogram for Overall Survival in Patients With Diffuse Large B‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Seminars in Hematology
Hematology
2015English

Global Hypomethylation Is an Independent Prognostic Factor in Diffuse Large B Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Secondary Cutaneous Diffuse Large B-Cell Lymphoma Has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-Cell Lymphoma, Leg Type

Acta Dermato-Venereologica
DermatologyMedicine
2016English

ALK -Positive Diffuse Large B-Cell Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Biomarkers of Diffuse Large B-Cell Lymphoma: Impact on Diagnosis, Treatment, and Prognosis

Current Biomarker Findings
BiochemistryClinical Biochemistry
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy